Amino Acids Regulate Cisplatin Insensitivity in Neuroblastoma

Area of Science:

• Pediatric Oncology
• Cancer Metabolism
• Drug Resistance Mechanisms

Background:

• Neuroblastoma, a pediatric cancer, has poor survival due to treatment resistance.
• Metabolic alterations contribute to cancer cell survival under chemotherapy.
• Mechanisms of cisplatin resistance in neuroblastoma remain poorly understood.

Purpose of the Study:

• Investigate metabolic changes in cisplatin-insensitive neuroblastoma cells.
• Determine the role of amino acid metabolism in neuroblastoma chemoresistance.
• Evaluate hydroxychloroquine (HCQ) as a therapeutic agent in combination with cisplatin (CDDP).

Main Methods:

• Comparative metabolomics analysis of cisplatin-sensitive and insensitive neuroblastoma cell lines.
• Assessment of cell survival and amino acid levels following amino acid depletion.
• Evaluation of hydroxychloroquine (HCQ) in combination with cisplatin (CDDP) on cell survival and metabolism.

Main Results:

• Cisplatin-insensitive neuroblastoma cells exhibit upregulated amino acid metabolism.
• Amino acid depletion significantly reduces neuroblastoma cell survival and cisplatin-insensitivity.
• Combination therapy with HCQ and CDDP abrogates amino acid metabolism and sensitizes cells to cisplatin.

Conclusions:

• Upregulated amino acid metabolism is a key mechanism in neuroblastoma cisplatin resistance.
• Targeting amino acid replenishment pathways, potentially via autophagy inhibition, can overcome chemoresistance.
• Combining autophagy inhibitors like HCQ with cisplatin offers a promising strategy for neuroblastoma treatment.